Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330

The CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) improves outcomes in some persons with acute myeloid leukemia (AML).[1][1] Because GO is ineffective in many patients and/or may have adverse effects, there is interest in understanding factors, including CD33 expression, that possibly